Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-002942-33
    Sponsor's Protocol Code Number:GWEP1428
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-10-15
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-002942-33
    A.3Full title of the trial
    A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P)
    Estudio aleatorizado doble ciego controlado con placebo de fase II para investigar las posibles interacciones fármaco-fármaco entre clobazam y cannabidiol (GWP42003-P)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to investigate the possible interaction between clobazam and cannabidiol.
    Un estudio para investigar la posible interacción entre clobazam y cannabidiol.
    A.4.1Sponsor's protocol code numberGWEP1428
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGW Research Ltd
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGW Research Ltd
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGW Research Ltd
    B.5.2Functional name of contact pointGW Research Ltd. Switchboard
    B.5.3 Address:
    B.5.3.1Street AddressSovereign House, Vision Park, Chivers Way
    B.5.3.2Town/ cityHiston, Cambridge
    B.5.3.3Post codeCB24 9BZ
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+34931850232
    B.5.5Fax number+34931850257
    B.5.6E-mailinfo@gwpharm.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCannabidiol (CBD)
    D.3.2Product code GWP42003-P
    D.3.4Pharmaceutical form Oral solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNN/A
    D.3.9.1CAS number 13956-29-1
    D.3.9.2Current sponsor codeGWP42003-P
    D.3.9.3Other descriptive nameCANNABIDIOL
    D.3.9.4EV Substance CodeSUB26600
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product Yes
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product Yes
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Noiafren
    D.2.1.1.2Name of the Marketing Authorisation holderSanofi Aventis, S.A.
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCLOBAZAM
    D.3.9.1CAS number 22316-47-8
    D.3.9.4EV Substance CodeSUB06673MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOral solution
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Epilepsy
    Epilepsia
    E.1.1.1Medical condition in easily understood language
    Epilepsy
    Epilepsia
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level PT
    E.1.2Classification code 10073677
    E.1.2Term Severe myoclonic epilepsy of infancy
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine whether GWP42003-P affects the pharmacokinetic (PK) profile of clobazam (CLB) and its primary metabolite N-desmethylclobazam (N-CLB).
    Determinar si GWP42003-P afecta el perfil farmacocinético (PK) de clobazam (CLB) y su principal metabolito N desmetilclobazam (N-CLB).
    E.2.2Secondary objectives of the trial
    To assess the safety and tolerability of GWP42003-P in the presence of CLB.
    Evaluar la seguridad y la tolerabilidad de GWP42003-P en presencia de CLB.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Male or female patients aged 18 to 55 years inclusive.
    • Patient must have epilepsy as determined by the investigator and be taking CLB.
    • Patient must have a documented magnetic resonance imaging/computerized tomography of the brain that ruled out a progressive neurologic condition.
    • Patient must have experienced at least one seizure of any type (i.e., convulsive: tonic-clonic, tonic, clonic, atonic; focal: focal seizures with retained consciousness and a motor component, focal seizures with impaired consciousness focal seizures evolving to bilateral secondary generalization) within the two months prior to randomization.
    • Patients must be taking CLB and no more than two other anti-epileptic drugs (AEDs) during the course of the study.
    • AED(s), including CLB, must be stable for four weeks prior to screening and regimen must remain stable throughout the duration of the blinded phase of the study.
    • Intervention with vagus nerve stimulation and/or ketogenic diet must be stable for four weeks prior to baseline and patient/caregiver must be willing to maintain a stable regimen throughout the blinded phase of the study.
    • Patients must abstain from alcohol during the blinded phase of the study.
    • Patient and/or legal representative is available to attend all PK visits within the required visit window.
    • Patient and/or legal representative must be willing and able to give informed consent for participation in the study
    • Patient and/or legal representative must be willing and able (in the investigator's opinion) to comply with all study requirements.
    • Patient is willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable.
    • Patient is willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study.
    • El paciente debe ser hombre o mujer de entre 18 y 55 años de edad, inclusive.
    • El paciente debe sufrir de epilepsia según lo determine el investigador y debe de estar tomando CLB.
    • Resonancia magnética/tomografía computarizada del cerebro documentadas que no muestren ninguna anormalidad neurológica progresiva.
    • El paciente debe haber sufrido al menos una crisis del tipo que fuere (es decir, convulsiva: tonicoclónica, tónica, clónica, atónica; focal: crisis focales sin pérdida de conocimiento y componente motor, crisis focales con pérdida de conocimiento que evolucionan a crisis generalizadas secundarias bilaterales) en los dos meses previos a la aleatorización.
    • El paciente debe estar tomando CLB y no más de otros dos fármacos antiepilépticos (FAEs) durante el estudio.
    • Los FAEs, incluido el CLB, deben haber estado estables durante cuatro semanas antes de la selección y el régimen debe permanecer estable durante toda la fase ciega del estudio.
    • Las intervenciones de estimulación del nervio vago y/o la dieta cetogénica deben haber sido estables durante cuatro semanas antes del periodo basal y el paciente y el cuidador están dispuestos a mantener un régimen estable durante toda la fase ciega del estudio.
    • El paciente debe abstenerse de consumir alcohol durante la fase ciega del estudio.
    • El paciente y/o su representante legal pueden acudir a todas las visitas para las evaluaciones de PK dentro del plazo de tiempo requerido para las visitas.
    • El paciente y/o su representante legal deben estar dispuestos y ser capaces de dar su consentimiento informado para participar en el estudio.
    • El paciente y/o su representante legal son capaces (en la opinión del investigador) y están dispuestos a cumplir todos los requerimientos del estudio.
    • El paciente debe estar dispuesto a permitir que se notifique su nombre y su participación en este estudio a las autoridades responsables, según corresponda.
    • El paciente debe estar dispuesto a permitir que se notifique su participación en el estudio a su médico de atención primaria y especialista, si fuera apropiado.
    E.4Principal exclusion criteria
    • Patient has clinically significant unstable medical conditions other than epilepsy.
    • Patients on CLB at doses above 20 mg per day.
    • Patients taking CLB intermittently as rescue medication.
    • Patient has a history of symptoms (e.g., dizziness, light-headedness, blurred vision, palpitations, weakness, syncope) related to a drop in blood pressure (BP) due to postural changes.
    • Any history of suicidal behavior or any suicidal ideation of type four or five on the C-SSRS in the last month or at screening.
    • Patient has had clinically relevant symptoms or a clinically significant illness in the four weeks prior to screening or enrollment, other than epilepsy.
    • Patient has consumed alcohol during the seven days prior to enrollment and is unwilling to abstain during the blinded phase of the study.
    • Patient is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid based medications (including Sativex®) within the three months prior to study entry.
    • Patient has any known or suspected history of any drug abuse or addiction.
    • Patient is unwilling to abstain from recreational or medicinal cannabis, or synthetic cannabinoid based medications (including Sativex) for the duration for the study.
    • Patient has consumed grapefruit or grapefruit juice seven days prior to enrollment and is unwilling to abstain from drinking grapefruit juice within seven days of PK visits.
    • Patient has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP, e.g., sesame oil
    • Female patient is of child bearing potential or male patient's partner is of child bearing potential; unless willing to ensure that they or their partner use highly effective contraception for the duration of the study and for three months thereafter. Highly effective methods of contraception are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly. Such methods include hormonal contraceptives, intrauterine devices/ hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence.
    • Female patient who is pregnant (positive pregnancy test), lactating or planning pregnancy during the course of the study and for three months thereafter.
    • Patients who have received an IMP within the 12 weeks prior to the screening visit.
    • Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, may influence the result of the study, or the patient's ability to participate in the study.
    • Following a physical examination, the patient has any abnormalities that, in the opinion of the investigator would prevent the participant from safe participation in the study.
    • Patient has significantly impaired hepatic function at screening (Visit 1) or enrollment (Visit 2), defined as any of the following:
    - Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >5 × upper limit of normal (ULN).
    - ALT or AST >3 × ULN and total bilirubin (TBL) >2 × ULN or international normalized ratio (INR) >1.5.
    - ALT or AST >3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
    This criterion can only be confirmed once the laboratory results are available; patients randomized into the study who are later found to meet this criterion must be withdrawn from the study.
    • Unwilling to abstain from donation of blood during the study.
    • Travel outside the country of residence planned during the study.
    • Patients previously enrolled into this study.
    • El paciente sufre alguna condición médica inestable clínicamente significativa, exceptuando epilepsia.
    • Pacientes que tomen dosis de CLB de más de 20 mg al día.
    • Pacientes que tomen CLB intermitentemente como medicamento de rescate.
    • El paciente tiene un historial de síntomas (p. ej., vértigo, mareos, visión borrosa, palpitaciones, debilidad, síncope) relacionados con una caída en la presión arterial (PA) debida a cambios posturales.
    • Historial de comportamiento suicida o cualquier ideación suicida de tipo cuatro o cinco en la escala C-SSRS en el último mes o en la visita de selección.
    • El paciente presenta síntomas clínicos relevantes o ha sufrido alguna enfermedad clínicamente significativa en las cuatro semanas previas a la visita de selección o participación, exceptuando la epilepsia.
    • El paciente ha consumido alcohol los 7 días previos a su inclusión y no está dispuesto a abstenerse durante la fase ciega del estudio.
    • El paciente utiliza en la actualidad o ha utilizado en el pasado, cannabis recreativo, cannabis medicinal o medicamentos sintéticos a base de cannabinoides (incluyendo Sativex®) tres meses antes de la participación en el estudio.
    • El paciente tiene historial o se sospecha que tiene historial de abuso o adicción a cualquier droga.
    • El paciente no está dispuesto a abstenerse de utilizar cannabis recreativo o medicinal o medicamentos a base de cannabinoides sintéticos (incluyendo Sativex) durante el estudio.
    • El paciente ha tomado pomelo o zumo de pomelo siete días antes de la participación y es reacio a abstenerse de tomar zumo de pomelo en los siete días antes de las visitas para las evaluaciones PK.
    • El paciente sufre o se sospecha que sufre alguna hipersensibilidad conocida a los cannabinoides o a alguno de los excipientes de MI, por ejemplo al aceite de sésamo.
    • Una paciente con potencial para procrear o un paciente cuya pareja tenga potencial para procrear; a menos que estén dispuestos a asegurar que tanto él como su pareja utilizarán métodos anticonceptivos altamente eficaces durante y tres meses después del estudio. Se definen como métodos anticonceptivos altamente eficaces aquellos que utilizados por sí solos o en combinación con otros, dan como resultado una tasa de error bajo (es decir, que no supere el 1% al año) cuando se usen de forma consistente y correcta. Estos métodos incluyen anticonceptivos hormonales, dispositivos intrauterinos / sistemas liberadores de hormonas, oclusión tubárica bilateral, pareja vasectomizada o abstinencia sexual.
    • Una paciente embarazada (prueba de embarazo positiva), que esté dando pecho o planificando un embarazo durante el transcurso del estudio y tres meses después del estudio.
    • Pacientes que han recibido un MI en los doce meses anteriores a la visita de selección.
    • Cualquier otra enfermedad o trastorno significativo que, según la opinión del investigador, podría poner en peligro al paciente al participar en el estudio, podría influir en el resultado del estudio o afectar la capacidad del paciente para participar en el estudio.
    • Después de un examen médico el paciente tiene alguna anormalidad que, según la opinión del investigador, pondría en riesgo la participación del paciente en el estudio de forma segura.
    • El paciente sufre disfunción hepática importante en la visita de selección (Visita 1) o inclusión (Visita 2), que pueda definirse como alguno de los siguientes:
    - Alanina aminotransferasa (ALT) o aspartato aminotransferasa (AST) >5 x límite superior normal (ULN).
    - ALT o AST >3 x ULN y bilirrubina total [TBL] >2 x ULN o razón internacional normalizada [INR] >1,5).
    - ALT o AST >3 × ULN con la aparición de fatiga, nauseas, vómitos, dolor o sensibilidad en el cuadrante superior derecho, fiebre, erupción y/o eosinofilia (>5%).
    Este criterio solamente puede confirmarse una vez de que estén disponibles los resultados de laboratorio; los pacientes aleatorizados en el estudio y que posteriormente se descubra que cumplen este criterio deben ser retirados del estudio.
    • El paciente es reacio a abstenerse de donar sangre durante el estudio.
    • El paciente tiene pensado viajar fuera de su país de residencia durante el estudio.
    • El paciente ha estado anteriormente aleatorizado en este estudio.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoints of the study are the PK parameters (Cmax, tmax, AUC(0–∞) AUC(0–t), t½) of the following analytes:
    • CLB
    • N-desmethylclobazam (N-CLB)
    • CBD
    •CBD major metabolites
    Las variables principales del estudio son los parámetros PK (Cmax, tmax, AUC(0–∞) AUC(0–t), t½) de los siguientes analitos:
    • CLB
    • N-desmetilclobazam (N-CLB)
    • CBD
    • Principales metabolitos de CBD
    E.5.1.1Timepoint(s) of evaluation of this end point
    From 'Visit 1' to the 'End of Blinded Treatment'
    De 'Visita 1' al 'Fin de Tratamiento Ciego'
    E.5.2Secondary end point(s)
    To assess the safety and tolerability of GWP42003-P compared with placebo when taken in combination with CLB. Safety and tolerability will be assessed using the following parameters:
    • AEs
    • 12-lead Electrocardiogram (ECG)
    • Clinical laboratory parameters (clinical chemistry, hematology and urinalysis)
    • Vital signs
    • Columbia-Suicide Severity Rating Scale (C-SSRS)
    • Seizure Frequency
    • Abuse liability
    PK parameters (Cmax, tmax, AUC(0–∞), AUC(0–t), t½) of the following analytes:
    • THC
    • THC major metabolites
    Evaluar la seguridad y la tolerabilidad de GWP42003-P comparado con el placebo cuando se tome en combinación con CLB. La seguridad y la tolerabilidad se evaluará utilizando los siguientes parámetros:
    • AAs
    • Electrocardiograma de 12 derivaciones (ECG)
    • Parámetros clínicos de laboratorio (química clínica, hematología y uroanálisis)
    • Signos vitales
    • Escala de calificación de la severidad del suicidio de Columbia (C-SSRS)
    • Frecuencia de las crisis
    • Propensión al abuso del uso del fármaco
    Parámetros PK (Cmax, tmax, AUC(0–∞), AUC(0–t), t½) de los siguientes analitos:
    • THC
    • Principales metabolitos de THC
    E.5.2.1Timepoint(s) of evaluation of this end point
    From 'Visit 1 to End of Study'
    De 'Visita 1 a Fin de Estudio'
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA2
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months8
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 20
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 20
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The study design includes an open-label extension that lasts for a year following the main PK phase of the study. Following the end of the protocol GW will discuss on a case-by-case basis the possibility of trial subjects receiving GWP42003-P, however there is no guarantee that all patients will be eligible to receive further treatment.
    El diseño del ensayo incluye un periodo de extensión abierto que tiene una duración de un año después de la fase PK principal del estudio. Tras la finalización del protocolo GW discutirá caso a caso sobre la posibilidad de los sujetos del ensayo de continuar recibiendo GWP42003-P, sin embargo no hay garantía de que todos los pacientes sean elegibles para recibir tratamiento adicional.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-11-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-11-06
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2017-06-07
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 00:03:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA